On Monday, Connecticut state governor, Ned Lamont, signed legislation that requires the state to study therapeutic potential associated with psilocybin mushrooms. The governor is likely to see a marijuana legalization bill on his desk. This will happen if the legislature approves it this week, but the governor has signed off a psychedelic policy proposal before then. The proposal is part of the wider package of health reform initiatives.
The provision requires that the mental Health and Addiction Service convene working groups. In the study, the provision requires that it includes legislators who are conversant with public health issues. The study should also include but not be limited to a test of whether psilocybin use by people under medical instructions may be beneficial to them.
Until January 1, 2022, the working group has to compile and issue a report on its findings to the legislature. The psilocybin proposal, in a separate bill, was also introduced, and the measures in the bill are related to behavioral and mental health.
Despite being vocal about separate legislation on cannabis legalization in the state, Lamont remained calm on the specifics of the psychedelic provision. In an hours-long meeting that spilled to Tuesday, the senate was cleared by the bill.
Most state legislatures are considering different reform proposals with respect to psychedelics before the next session begins. A new bill was introduced last week by New York lawmakers that requires the state to develop an institution that will research the therapeutic potentials of psychedelics.
In Texas, a similar bill to that of New York that requires the state to have an institute that will study psychedelic therapeutic potentials was delivered to the governor’s desk. Last week, the California Senate approved a bill set to legalize psychedelic possession, including DMT, LSD, and ibogaine.
Oregon voters also approved ballot measures as they tried to create a program of its kind. The program was set to see people treated in a clinical setting using psychedelics.